{"id":"adjuvant-nivolumab","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Rash"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"3-5","effect":"Immune-mediated pneumonitis"},{"rate":"2-4","effect":"Immune-mediated hepatitis"},{"rate":"2-3","effect":"Immune-mediated colitis"},{"rate":"5-10","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the PD-1 checkpoint, nivolumab restores T cell activation and proliferation, allowing the immune system to recognize and attack cancer cells more effectively. In the adjuvant setting, it is used after surgical resection to reduce the risk of recurrence and improve overall survival by maintaining enhanced anti-tumor immune responses.","oneSentence":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:11.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of melanoma (resected stage IIIB/IIIC/IV)"},{"name":"Adjuvant treatment of non-small cell lung cancer (resected stage IB-IIIA)"}]},"trialDetails":[{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT02595944","phase":"PHASE3","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":903},{"nctId":"NCT05111574","phase":"PHASE2","title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-11","conditions":"Anal Melanoma, Bladder Melanoma, Cervical Melanoma","enrollment":101},{"nctId":"NCT05907122","phase":"PHASE3","title":"A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-07-26","conditions":"Melanoma","enrollment":256},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT04930783","phase":"PHASE1","title":"NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-01-03","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT05987241","phase":"PHASE2, PHASE3","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-02","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma","enrollment":992},{"nctId":"NCT07195695","phase":"PHASE3","title":"Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-01-16","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04817254","phase":"PHASE2","title":"Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Glioblastoma, Gliosarcoma, Malignant Glioma","enrollment":47},{"nctId":"NCT07476326","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-06-01","conditions":"Melanoma","enrollment":120},{"nctId":"NCT06863311","phase":"PHASE2","title":"Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC","status":"RECRUITING","sponsor":"Karie Runcie","startDate":"2026-03-13","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":70},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT06534983","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-12-09","conditions":"Muscle-invasive Urothelial Carcinoma","enrollment":362},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT06275360","phase":"PHASE2","title":"Repositioning Immunotherapy in VetArans With Lung Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-03-01","conditions":"Non-Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT04741997","phase":"EARLY_PHASE1","title":"Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-05-24","conditions":"Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation","enrollment":50},{"nctId":"NCT03358719","phase":"PHASE1","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-03-27","conditions":"Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":8},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT04848519","phase":"PHASE2","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":6},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":"Genitourinary Cancers","enrollment":500},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT03829722","phase":"PHASE2","title":"Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-09-05","conditions":"Oropharynx Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT02656706","phase":"PHASE2","title":"Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brown University","startDate":"2016-07","conditions":"Melanoma","enrollment":22},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT06816927","phase":"PHASE2","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-28","conditions":"Newly Diagnosed Glioblastoma","enrollment":92},{"nctId":"NCT05002569","phase":"PHASE3","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-10-19","conditions":"Melanoma","enrollment":1093},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT03171025","phase":"PHASE2","title":"Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2017-07-10","conditions":"Bladder Cancer","enrollment":200},{"nctId":"NCT02989636","phase":"PHASE1","title":"Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-03-10","conditions":"Chordoma","enrollment":21},{"nctId":"NCT03405155","phase":"PHASE2","title":"Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-01-17","conditions":"Melanoma (Skin)","enrollment":26},{"nctId":"NCT05480384","phase":"PHASE2","title":"Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brown University","startDate":"2023-07-14","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression","enrollment":1},{"nctId":"NCT04960709","phase":"PHASE3","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-08-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":712},{"nctId":"NCT06584435","phase":"PHASE2","title":"A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-10-10","conditions":"High-risk Renal Cell Carcinoma","enrollment":100},{"nctId":"NCT04658147","phase":"PHASE1","title":"Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-05-28","conditions":"Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT07031765","phase":"PHASE1","title":"Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-07-25","conditions":"Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma","enrollment":12},{"nctId":"NCT04966663","phase":"PHASE2","title":"Using ctDNA to Determine Therapies for Lung Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-03-28","conditions":"Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA","enrollment":66},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT02451982","phase":"PHASE2","title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-28","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT03383458","phase":"PHASE3","title":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-04-18","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":545},{"nctId":"NCT05254184","phase":"PHASE1","title":"KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-01","conditions":"Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT02743494","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-07-14","conditions":"Advanced Cancer","enrollment":794},{"nctId":"NCT04013854","phase":"PHASE2","title":"Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-01-01","conditions":"Melanoma Stage III, Melanoma","enrollment":67},{"nctId":"NCT05704933","phase":"EARLY_PHASE1","title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-06-06","conditions":"Metastatic Melanoma, Metastasis to Brain","enrollment":1},{"nctId":"NCT04025879","phase":"PHASE3","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":461},{"nctId":"NCT02632409","phase":"PHASE3","title":"An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2016-03-22","conditions":"Various Advanced Cancer","enrollment":709},{"nctId":"NCT05350501","phase":"PHASE2","title":"EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer","status":"TERMINATED","sponsor":"Enterome","startDate":"2023-03-01","conditions":"Colorectal Cancer","enrollment":1},{"nctId":"NCT04400539","phase":"PHASE2","title":"The IMmunotherapy Pleural 5-ALA PDT","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-05-09","conditions":"Mesotheliomas Pleural, Malignant Pleural Mesothelioma","enrollment":20},{"nctId":"NCT04912765","phase":"PHASE2","title":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2021-04-15","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT03298893","phase":"PHASE1, PHASE2","title":"Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2017-11-27","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer","enrollment":21},{"nctId":"NCT07092670","phase":"","title":"MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.","status":"RECRUITING","sponsor":"Intergruppo Melanoma Italiano","startDate":"2025-08-04","conditions":"Melanoma, Fertility","enrollment":270},{"nctId":"NCT04099251","phase":"PHASE3","title":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-10-28","conditions":"Melanoma","enrollment":790},{"nctId":"NCT04620200","phase":"PHASE2","title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-08-11","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT03984357","phase":"PHASE2","title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-03-16","conditions":"Nasopharyngeal Carcinoma","enrollment":152},{"nctId":"NCT02990611","phase":"","title":"Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-12-06","conditions":"Melanoma","enrollment":1087},{"nctId":"NCT05779592","phase":"","title":"A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-11-23","conditions":"Muscle-invasive Urothelial Carcinoma","enrollment":400},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03341936","phase":"PHASE2","title":"Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-03-15","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":29},{"nctId":"NCT03114163","phase":"","title":"Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-12","conditions":"Head and Neck Cancer","enrollment":485},{"nctId":"NCT04006262","phase":"PHASE2","title":"Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-10-23","conditions":"Localized Oesogastric Adenocarcimona, MSI and or dMMR","enrollment":32},{"nctId":"NCT06421311","phase":"","title":"Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2024-07-30","conditions":"Urothelial Carcinoma","enrollment":176},{"nctId":"NCT06499298","phase":"","title":"Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-12-03","conditions":"Esophageal Cancer, Gastroesophageal Junction Cancer","enrollment":64},{"nctId":"NCT03406247","phase":"PHASE2","title":"Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-02-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":140},{"nctId":"NCT06586255","phase":"PHASE1","title":"Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2025-04-29","conditions":"Urothelial Carcinoma Bladder, Bladder Cancer","enrollment":10},{"nctId":"NCT03576417","phase":"PHASE3","title":"A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2018-10-10","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":680},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04323046","phase":"PHASE1","title":"Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults","status":"RECRUITING","sponsor":"Sabine Mueller, MD, PhD","startDate":"2020-10-02","conditions":"Glioblastoma, Malignant Glioma, Recurrent Glioblastoma","enrollment":20},{"nctId":"NCT02388906","phase":"PHASE3","title":"Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03-16","conditions":"Melanoma","enrollment":906},{"nctId":"NCT06101134","phase":"PHASE2","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-11-06","conditions":"Melanoma","enrollment":100},{"nctId":"NCT05684276","phase":"PHASE2","title":"DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2023-05-12","conditions":"NSCLC, Pancoast Tumor","enrollment":22},{"nctId":"NCT04564157","phase":"PHASE3","title":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-01-13","conditions":"Non-Small Cell Lung Cancer, Adjuvant Chemotherapy","enrollment":210},{"nctId":"NCT02196961","phase":"PHASE2","title":"Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation","status":"COMPLETED","sponsor":"Prof. Dr. med. Dirk Schadendorf","startDate":"2014-06","conditions":"Merkel Cell Carcinoma","enrollment":180},{"nctId":"NCT03838159","phase":"PHASE2","title":"NADIM II: Neo-Adjuvant Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2019-05-15","conditions":"Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06682728","phase":"PHASE2","title":"Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-11-15","conditions":"Urothelial Carcinoma, Muscle-invasive Bladder Cancer","enrollment":23},{"nctId":"NCT04330430","phase":"PHASE2","title":"Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-09-08","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":24},{"nctId":"NCT04133948","phase":"PHASE1, PHASE2","title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-01-07","conditions":"Malignant Melanoma Stage III","enrollment":44},{"nctId":"NCT03387761","phase":"PHASE1","title":"Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-01-15","conditions":"Urothelial Carcinoma","enrollment":54},{"nctId":"NCT05297565","phase":"PHASE3","title":"A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-08-02","conditions":"Melanoma","enrollment":14},{"nctId":"NCT04627246","phase":"PHASE1","title":"Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Pancreatic Adenocarcinoma","enrollment":14},{"nctId":"NCT03721757","phase":"PHASE2","title":"CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer","status":"COMPLETED","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2019-05-10","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":21},{"nctId":"NCT03138161","phase":"PHASE1, PHASE2","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2017-04-13","conditions":"Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma","enrollment":250},{"nctId":"NCT03047928","phase":"PHASE1, PHASE2","title":"Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2018-02-22","conditions":"Metastatic Melanoma","enrollment":48},{"nctId":"NCT03576612","phase":"PHASE1","title":"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2018-02-27","conditions":"Glioma, Malignant","enrollment":41},{"nctId":"NCT04177953","phase":"PHASE2","title":"Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2019-02-04","conditions":"Pleural Mesothelioma Malignant","enrollment":92},{"nctId":"NCT04146324","phase":"","title":"An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-12","conditions":"Melanoma","enrollment":150},{"nctId":"NCT06097975","phase":"PHASE1","title":"A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2024-03-15","conditions":"Recurrent Glioblastoma","enrollment":18},{"nctId":"NCT04382664","phase":"PHASE2","title":"UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma","status":"COMPLETED","sponsor":"Ultimovacs ASA","startDate":"2020-05-27","conditions":"Malignant Melanoma","enrollment":156},{"nctId":"NCT03715946","phase":"PHASE2","title":"Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer","status":"COMPLETED","sponsor":"Robert L. Ferris, MD, PhD","startDate":"2018-11-16","conditions":"Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT03138512","phase":"PHASE3","title":"A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-07","conditions":"Carcinoma, Renal Cell","enrollment":1641},{"nctId":"NCT04195139","phase":"PHASE2","title":"Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2018-02-22","conditions":"Glioblastoma Multiforme","enrollment":103},{"nctId":"NCT03081689","phase":"PHASE2","title":"Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2017-04-15","conditions":"Non Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT03487666","phase":"PHASE2","title":"OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2018-05-21","conditions":"Triple Negative Breast Cancer","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":246,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Opdivo"],"phase":"phase_3","status":"active","brandName":"Adjuvant nivolumab","genericName":"Adjuvant nivolumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immunity. Used for Adjuvant treatment of melanoma (resected stage IIIB/IIIC/IV), Adjuvant treatment of non-small cell lung cancer (resected stage IB-IIIA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}